• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

    0.8249 +0.0451 (+5.78%)
    Streaming Delayed Price Updated: 11:27 AM EDT, Mar 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Werewolf Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Announces Pipeline and Business Updates
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the BIO International Convention
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in Upcoming Investor Conferences
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.